Clinical Syndromes: Aspergillus

  • Rosa Bellmann-WeilerEmail author
  • Romuald Bellmann


Invasive Aspergillus infection (IAI) is the second most common invasive fungal infection among patients with hematological malignancies. Systemic infection with Aspergillus spp. is potentially life-threatening for patients suffering from severe diseases.

Persons at risk have severe and prolonged immunosuppression and may suffer from a hematological malignancy (in the first-line patients with acute myeloid leukemia and recipients of allogeneic HSCT). Moreover solid organ transplant recipients and patients treated with corticosteroids for exacerbated COPD or with multiple myeloma are increasingly at risk for IAI. The most important risk factor is particularly severe granulocytopenia (<0.5 G/L), but other risk factors also include AIDS in a progressive stage and also intensive care patients with corticosteroid treatment, lung disease, and renal failure. Additionally, patients who have to take immunosuppressive drugs other than corticosteroids or those suffering from inherited immunodeficiency may develop a severe Aspergillus infection.


  1. 1.
    Kontoyiannis DP, Marr KA, Park BJ, Alexander BD, Anaissie EJ, Walsh TJ et al (2010) Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clin Infect Dis 50(8):1091–1100PubMedCrossRefGoogle Scholar
  2. 2.
    Meersseman W, Lagrou K, Maertens J, Van Wijngaerden E (2007) Invasive aspergillosis in the intensive care unit. Clin Infect Dis 45(2):205–216PubMedCrossRefGoogle Scholar
  3. 3.
    Herbrecht R, Bories P, Moulin JC, Ledoux MP, Letscher-Bru V (2012) Risk stratification for invasive aspergillosis in immunocompromised patients. Ann N Y Acad Sci 1272:23–30PubMedCrossRefGoogle Scholar
  4. 4.
    Meersseman W, Vandecasteele SJ, Wilmer A, Verbeken E, Peetermans WE, Van Wijngaerden E (2004) Invasive aspergillosis in critically ill patients without malignancy. Am J Respir Crit Care Med 170:621–625PubMedCrossRefGoogle Scholar
  5. 5.
    Wojtowicz A, Gresnigt MS, Lecompte T, Bibert S, Manuel O, Joosten LA et al (2015) IL1B and DEFB1 polymorphisms increase susceptibility to invasive mold infection after solid-organ transplantation. J Infect Dis 211(10):1646–1657PubMedCrossRefGoogle Scholar
  6. 6.
    Gregg KS, Kauffman CA (2015) Invasive aspergillosis: epidemiology, clinical aspects, and treatment. Semin Respir Crit Care Med 36(5):662–672PubMedCrossRefGoogle Scholar
  7. 7.
    Klingspor L, Saaedi B, Ljungman P, Szakos A (2015) Epidemiology and outcomes of patients with invasive mould infections: a retrospective observational study from a single centre (2005-2009). Mycoses 58(8):470–477PubMedCrossRefGoogle Scholar
  8. 8.
    Wingard JR, Ribaud P, Schlamm HT, Herbrecht R (2008) Changes in causes of death over time after treatment for invasive aspergillosis. Cancer 112(10):2309–2312PubMedCrossRefGoogle Scholar
  9. 9.
    Lewis RE, Cahyame-Zuniga L, Leventakos K, Chamilos G, Ben-Ami R, Tamboli P et al (2013) Epidemiology and sites of involvement of invasive fungal infections in patients with haematological malignancies: a 20-year autopsy study. Mycoses 56(6):638–645PubMedCrossRefGoogle Scholar
  10. 10.
    Pappas PG, Alexander BD, Andes DR, Hadley S, Kauffman CA, Freifeld A et al (2010) Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). Clin Infect Dis 50(8):1101–1111PubMedCrossRefGoogle Scholar
  11. 11.
    Johnson EM, Oakley KL, Radford SA, Moore CB, Warn P, Warnock DW et al (2000) Lack of correlation of in vitro amphotericin B susceptibility testing with outcome in a murine model of Aspergillus infection. J Antimicrob Chemother 45(1):85–93PubMedCrossRefGoogle Scholar
  12. 12.
    De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T et al (2008) Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 46(12):1813–1821PubMedPubMedCentralCrossRefGoogle Scholar
  13. 13.
    Liss B, Vehreschild JJ, Bangard C, Maintz D, Frank K, Gronke S et al (2015) Our 2015 approach to invasive pulmonary aspergillosis. Mycoses 58(6):375–382PubMedCrossRefGoogle Scholar
  14. 14.
    Patterson TF, Thompson GR, Denning DW, Fishman JA, Hadley S, Herbrecht R et al (2016) Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis 63(4):e1–e60PubMedPubMedCentralCrossRefGoogle Scholar
  15. 15.
    Maertens J, Groll AH, Cordonnier C, de la Camara R, Roilides E, Marchetti O (2011) Treatment and timing in invasive mould disease. J Antimicrob Chemother 66(Suppl 1):i37–i43CrossRefGoogle Scholar
  16. 16.
    Tissot F, Agrawal S, Pagano L, Petrikkos G, Groll AH, Skiada A et al (2017) ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients. Haematologica 102(3):433–444PubMedPubMedCentralCrossRefGoogle Scholar
  17. 17.
    Parry MF, Coughlin FR, Zambetti FX (1982) Aspergillus empyema. Chest 81(6):768–770PubMedCrossRefGoogle Scholar
  18. 18.
    Hoenigl M, Krause R (2013) Antifungal therapy of aspergillosis of the central nervous system and aspergillus endophthalmitis. Curr Pharm Des 19(20):3648–3668PubMedCrossRefGoogle Scholar
  19. 19.
    McCarthy M, Rosengart A, Schuetz AN, Kontoyiannis DP, Walsh TJ (2014) Mold infections of the central nervous system. N Engl J Med 371(2):150–160PubMedPubMedCentralCrossRefGoogle Scholar
  20. 20.
    Endo T, Tominaga T, Konno H, Yoshimoto T (2002) Fatal subarachnoid hemorrhage, with brainstem and cerebellar infarction, caused by Aspergillus infection after cerebral aneurysm surgery: case report. Neurosurgery 50(5):1147–1150 discussion 50-1PubMedGoogle Scholar
  21. 21.
    Levin LA, Avery R, Shore JW, Woog JJ, Baker AS (1996) The spectrum of orbital aspergillosis: a clinicopathological review. Surv Ophthalmol 41(2):142–154PubMedCrossRefGoogle Scholar
  22. 22.
    Gonzalez-Vicent M, Diaz MA, Colmenero I, Sevilla J, Madero L (2008) Primary gastrointestinal aspergillosis after autologous peripheral blood progenitor cell transplantation: an unusual presentation of invasive aspergillosis. Transpl Infect Dis 10(3):193–196PubMedCrossRefGoogle Scholar
  23. 23.
    Denning DW (2001) Chronic forms of pulmonary aspergillosis. Clin Microbiol Infect 7(Suppl 2):25–31PubMedCrossRefGoogle Scholar
  24. 24.
    Patterson TF, Thompson GR, Denning DW, Fishman JA, Hadley S, Herbrecht R et al (2016) Executive summary: practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis 63(4):433–442PubMedPubMedCentralCrossRefGoogle Scholar
  25. 25.
    Vinh DC (2011) Insights into human antifungal immunity from primary immunodeficiencies. Lancet Infect Dis 11(10):780–792PubMedCrossRefGoogle Scholar
  26. 26.
    Andes DR, Safdar N, Baddley JW, Alexander B, Brumble L, Freifeld A et al (2016) The epidemiology and outcomes of invasive Candida infections among organ transplant recipients in the United States: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). Transpl Infect Dis 18(6):921–931PubMedCrossRefGoogle Scholar
  27. 27.
    Muldoon EG, Strek ME, Patterson KC (2017) Allergic and noninvasive infectious pulmonary aspergillosis syndromes. Clin Chest Med 38(3):521–534PubMedCrossRefGoogle Scholar
  28. 28.
    O’Brien SN, Blijlevens NM, Mahfouz TH, Anaissie EJ (2003) Infections in patients with hematological cancer: recent developments. Hematology Am Soc Hematol Educ Program 2003:438–472CrossRefGoogle Scholar
  29. 29.
    Leather HL, Wingard JR (2006) New strategies of antifungal therapy in hematopoietic stem cell transplant recipients and patients with hematological malignancies. Blood Rev 20(5):267–287PubMedCrossRefGoogle Scholar
  30. 30.
    Cornely OA, Maertens J, Winston DJ, Perfect J, Ullmann AJ, Walsh TJ et al (2007) Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 356(4):348–359PubMedPubMedCentralCrossRefGoogle Scholar
  31. 31.
    Ullmann AJ, Lipton JH, Vesole DH, Chandrasekar P, Langston A, Tarantolo SR et al (2007) Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 356(4):335–347PubMedCrossRefGoogle Scholar
  32. 32.
    Wingard JR, Carter SL, Walsh TJ, Kurtzberg J, Small TN, Baden LR et al (2010) Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation. Blood 116(24):5111–5118PubMedPubMedCentralCrossRefGoogle Scholar
  33. 33.
    Cordonnier C, Rovira M, Maertens J, Olavarria E, Faucher C, Bilger K et al (2010) Voriconazole for secondary prophylaxis of invasive fungal infections in allogeneic stem cell transplant recipients: results of the VOSIFI study. Haematologica 95(10):1762–1768PubMedPubMedCentralCrossRefGoogle Scholar
  34. 34.
    van Burik JA, Ratanatharathorn V, Stepan DE, Miller CB, Lipton JH, Vesole DH et al (2004) Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis 39(10):1407–1416Google Scholar
  35. 35.
    Maertens J, Theunissen K, Verhoef G, Verschakelen J, Lagrou K, Verbeken E et al (2005) Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study. Clin Infect Dis 41(9):1242–1250PubMedCrossRefGoogle Scholar
  36. 36.
    Nivoix Y, Leveque D, Herbrecht R, Koffel JC, Beretz L, Ubeaud-Sequier G (2008) The enzymatic basis of drug-drug interactions with systemic triazole antifungals. Clin Pharmacokinet 47(12):779–792PubMedCrossRefGoogle Scholar
  37. 37.
    Malani AN, Kerr LE, Kauffman CA (2015) Voriconazole: how to use this antifungal agent and what to expect. Semin Respir Crit Care Med 36(5):786–795PubMedCrossRefGoogle Scholar
  38. 38.
    Walsh TJ, Raad I, Patterson TF, Chandrasekar P, Donowitz GR, Graybill R et al (2007) Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis 44(1):2–12PubMedCrossRefGoogle Scholar
  39. 39.
    Maertens JA, Raad II, Marr KA, Patterson TF, Kontoyiannis DP, Cornely OA et al (2016) Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial. Lancet 387(10020):760–769PubMedPubMedCentralCrossRefGoogle Scholar
  40. 40.
    Heinz WJ, Buchheidt D, Ullmann AJ (2016) Clinical evidence for caspofungin monotherapy in the first-line and salvage therapy of invasive Aspergillus infections. Mycoses 59(8):480–493PubMedCrossRefGoogle Scholar
  41. 41.
    Kartsonis NA, Saah AJ, Joy LC, Taylor AF, Sable CA (2005) Salvage therapy with caspofungin for invasive aspergillosis: results from the caspofungin compassionate use study. J Infect 50(3):196–205PubMedCrossRefGoogle Scholar
  42. 42.
    Maertens J, Raad I, Petrikkos G, Boogaerts M, Selleslag D, Petersen FB et al (2004) Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis 39(11):1563–1571PubMedCrossRefGoogle Scholar
  43. 43.
    Hiemenz JW, Raad II, Maertens JA, Hachem RY, Saah AJ, Sable CA et al (2010) Efficacy of caspofungin as salvage therapy for invasive aspergillosis compared to standard therapy in a historical cohort. Eur J Clin Microbiol Infect Dis 29(11):1387–1394PubMedCrossRefGoogle Scholar
  44. 44.
    Walsh TJ, Teppler H, Donowitz GR, Maertens JA, Baden LR, Dmoszynska A et al (2004) Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 351(14):1391–1402PubMedCrossRefGoogle Scholar
  45. 45.
    Caillot D, Thiebaut A, Herbrecht R, de Botton S, Pigneux A, Bernard F et al (2007) Liposomal amphotericin B in combination with caspofungin for invasive aspergillosis in patients with hematologic malignancies: a randomized pilot study (Combistrat trial). Cancer 110(12):2740–2746PubMedCrossRefGoogle Scholar
  46. 46.
    Maertens J, Glasmacher A, Herbrecht R, Thiebaut A, Cordonnier C, Segal BH et al (2006) Multicenter, noncomparative study of caspofungin in combination with other antifungals as salvage therapy in adults with invasive aspergillosis. Cancer 107(12):2888–2897PubMedCrossRefGoogle Scholar
  47. 47.
    Marr KA, Schlamm HT, Herbrecht R, Rottinghaus ST, Bow EJ, Cornely OA et al (2015) Combination antifungal therapy for invasive aspergillosis: a randomized trial. Ann Intern Med 162(2):81–89PubMedCrossRefGoogle Scholar
  48. 48.
    Stevens DA, Schwartz HJ, Lee JY, Moskovitz BL, Jerome DC, Catanzaro A et al (2000) A randomized trial of itraconazole in allergic bronchopulmonary aspergillosis. N Engl J Med 342(11):756–762PubMedCrossRefGoogle Scholar
  49. 49.
    Camuset J, Nunes H, Dombret MC, Bergeron A, Henno P, Philippe B et al (2007) Treatment of chronic pulmonary aspergillosis by voriconazole in nonimmunocompromised patients. Chest 131(5):1435–1441PubMedCrossRefGoogle Scholar
  50. 50.
    van Burik JA, Colven R, Spach DH (1998) Cutaneous aspergillosis. J Clin Microbiol 36(11):3115–3121Google Scholar
  51. 51.
    van Burik JA, Colven R, Spach DH (1998) Itraconazole therapy for primary cutaneous aspergillosis in patients with AIDS. Clin Infect Dis 27(3):643–644PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Internal Medicine IIMedical University of InnsbruckInnsbruckAustria
  2. 2.Clinical Pharmacokinetics Unit, Division of Intensive Care and Emergency Medicine, Department of Internal Medicine IMedical University of InnsbruckInnsbruckAustria

Personalised recommendations